| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kai Zhang, Shipan Miao, Yitan Yao, Yating Yang, Shengya Shi, Bei Luo, Mengdie Li, Ling Zhang, Huanzhong Li. Efficacy and safety of prophylactic use of benzhexol after risperidone treatment. Heliyon. vol 9. issue 3. 2023-03-17. PMID:36925546. |
to test the effect of prophylactic use of benzhexol in schizophrenia patients after risperidone treatment. |
2023-03-17 |
2023-08-14 |
Not clear |
| Kai Zhang, Shipan Miao, Yitan Yao, Yating Yang, Shengya Shi, Bei Luo, Mengdie Li, Ling Zhang, Huanzhong Li. Efficacy and safety of prophylactic use of benzhexol after risperidone treatment. Heliyon. vol 9. issue 3. 2023-03-17. PMID:36925546. |
prophylactic use of benzhexol reduced extrapyramidal symptom in schizophrenia patients after risperidone treatment and did not affect the antipsychotic action of risperidone. |
2023-03-17 |
2023-08-14 |
Not clear |
| Ana Lokmer, Charanraj Goud Alladi, Réjane Troudet, Delphine Bacq-Daian, Anne Boland-Auge, Violaine Latapie, Jean-François Deleuze, Ravi Philip RajKumar, Deepak Gopal Shewade, Frank Bélivier, Cynthia Marie-Claire, Stéphane Jamai. Risperidone response in patients with schizophrenia drives DNA methylation changes in immune and neuronal systems. Epigenomics. 2023-03-15. PMID:36919681. |
risperidone response in patients with schizophrenia drives dna methylation changes in immune and neuronal systems. |
2023-03-15 |
2023-08-14 |
Not clear |
| Somdatta Saha, Javier González-Maes. The crosstalk between 5-HT Neuropharmacology. 2023-03-08. PMID:36889432. |
first generation or typical such as haloperidol and second generation or atypical such as clozapine and risperidone remain the current standard for schizophrenia treatment. |
2023-03-08 |
2023-08-14 |
Not clear |
| Monire Karbalaee, Melika Jameie, Mobina Amanollahi, Fateme TaghaviZanjani, Mohammadamin Parsaei, Fatemeh A Basti, Saba Mokhtari, Kamyar Moradi, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzade. Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Schizophrenia research. vol 254. 2023-02-22. PMID:36805834. |
this study investigated the efficacy and safety of fingolimod adjuvant to risperidone in schizophrenia treatment. |
2023-02-22 |
2023-08-14 |
Not clear |
| Robert Rosenheck, Sonia T Anand, Stephen G Kurtz, Cynthia Hau, Diane Smedberg, James F Pontzer, Ryan E Ferguson, Cynthia R Davi. Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration. Trials. vol 24. issue 1. 2023-02-07. PMID:36747254. |
a multisite randomized veterans health administration (vha) cooperative study (csp#555) published in 2011 compared the first long-acting injectable (lai) second-generation antipsychotic (sga), risperidone consta®, in veterans with a diagnosis of schizophrenia or schizoaffective disorder, to oral antipsychotics, with unexpected null results for effectiveness and cost-effectiveness. |
2023-02-07 |
2023-08-14 |
Not clear |
| Robert Litman, Dieter Naber, Lourdes Anta, Javier Martínez, Yuriy Filts, Christoph U Correl. Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM. Neuropsychiatric disease and treatment. vol 19. 2023-02-01. PMID:36721796. |
personal and social functioning and health-related quality of life in patients with schizophrenia treated with the long-acting injectable antipsychotic risperidone ism. |
2023-02-01 |
2023-08-14 |
Not clear |
| Robert Litman, Dieter Naber, Lourdes Anta, Javier Martínez, Yuriy Filts, Christoph U Correl. Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM. Neuropsychiatric disease and treatment. vol 19. 2023-02-01. PMID:36721796. |
to analyze the effect of risperidone ism on social functioning and health-related quality of life (hr-qol) in both short- and long-term treatment of patients with schizophrenia. |
2023-02-01 |
2023-08-14 |
Not clear |
| Nian-Sheng Tzeng, Yu-Yin Yang, Chen-Cheng Lin, Po-Shiuan Hsieh, Yia-Ping Li. Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia. Journal of integrative neuroscience. vol 22. issue 1. 2023-02-01. PMID:36722248. |
effects of early risperidone treatment on metabolic parameters in socially isolated rats-implication of antipsychotic intervention across developmental stages of schizophrenia. |
2023-02-01 |
2023-08-14 |
Not clear |
| Nian-Sheng Tzeng, Yu-Yin Yang, Chen-Cheng Lin, Po-Shiuan Hsieh, Yia-Ping Li. Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia. Journal of integrative neuroscience. vol 22. issue 1. 2023-02-01. PMID:36722248. |
the present study examined the hypothesis that schizophrenia itself but not risperidone, an extensively employed sga, is accountable for metabolic abnormalities. |
2023-02-01 |
2023-08-14 |
Not clear |
| Yusuke Okada, Ken Inada, Manabu Akazaw. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan. Schizophrenia research. vol 252. 2023-01-27. PMID:36706475. |
to compare the effectiveness of different long-acting injectable antipsychotics (lais) (aripiprazole, paliperidone, risperidone, and fluphenazine/haloperidol) in patients with schizophrenia in japan. |
2023-01-27 |
2023-08-14 |
Not clear |
| Huihui Du, Jingsong Ma, Wei Zhou, Mo Li, Cong Huai, Lu Shen, Hao Wu, Xianglong Zhao, Na Zhang, Songyin Gao, Qi Wang, Lin He, Xuming Wu, Shengying Qin, Mingzhe Zha. Methylome-wide association study of different responses to risperidone in schizophrenia. Frontiers in pharmacology. vol 13. 2023-01-09. PMID:36618913. |
methylome-wide association study of different responses to risperidone in schizophrenia. |
2023-01-09 |
2023-08-14 |
Not clear |
| Xiaofen Zong, Jiangbo Zhang, Lei Li, Tao Yao, Simeng Ma, Lijun Kang, Nan Zhang, Zhaowen Nie, Zhongchun Liu, Junjie Zheng, Xujun Duan, Maolin H. Virtual histology of morphometric similarity network after risperidone monotherapy and imaging-epigenetic biomarkers for treatment response in first-episode schizophrenia. Asian journal of psychiatry. vol 80. 2022-12-31. PMID:36586357. |
virtual histology of morphometric similarity network after risperidone monotherapy and imaging-epigenetic biomarkers for treatment response in first-episode schizophrenia. |
2022-12-31 |
2023-08-14 |
Not clear |
| Mahmoud S Abdallah, Esraa M Mosalam, Ahmed Hassan, Ahmed N Ramadan, Hend Omara-Reda, Abdel-Aziz A Zidan, Waad A Samman, Eman I El-Berr. Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial. CNS neuroscience & therapeutics. 2022-11-07. PMID:36341700. |
the aim of this study was to explore the effectiveness and safety of pentoxifylline as an adjuvant to risperidone in mitigating the negative symptoms in patients with chronic schizophrenia. |
2022-11-07 |
2023-08-14 |
Not clear |
| Jia Liu, Lidan Cao, Jing W. Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China. Frontiers in public health. vol 10. 2022-10-03. PMID:36187655. |
to evaluate the cost-effectiveness of lurasidone compared with olanzapine and risperidone in the first-line treatment of patients with schizophrenia from a chinese healthcare system perspective. |
2022-10-03 |
2023-08-14 |
Not clear |
| Maolin Hu, Yan Xia, Xiaofen Zong, John A Sweeney, Jeffrey R Bishop, Yanhui Liao, Gina Giase, Bingshan Li, Leah H Rubin, Yunpeng Wang, Zongchang Li, Ying He, Xiaogang Chen, Chunyu Liu, Chao Chen, Jinsong Tan. Risperidone-induced changes in DNA methylation in peripheral blood from first-episode schizophrenia patients parallel changes in neuroimaging and cognitive phenotypes. Psychiatry research. vol 317. 2022-09-08. PMID:36075150. |
second generation antipsychotics such as risperidone are first-line pharmacotherapy treatment choices for schizophrenia. |
2022-09-08 |
2023-08-14 |
Not clear |
| Cecilio Álam. Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review. Advances in therapy. 2022-09-01. PMID:36048404. |
risperidone ism as a new option in the clinical management of schizophrenia: a narrative review. |
2022-09-01 |
2023-08-14 |
Not clear |
| Ariel Ruiz de Villa, Asad A Haider, Leora Frimer, Yvette Bazikia. Oculogyric Crisis in the Setting of Low Dose Risperidone and Benztropine Mesylate Use in a Patient With Schizophrenia: A Case Report and Review of Literature. Cureus. vol 14. issue 7. 2022-08-29. PMID:36035042. |
oculogyric crisis in the setting of low dose risperidone and benztropine mesylate use in a patient with schizophrenia: a case report and review of literature. |
2022-08-29 |
2023-08-14 |
Not clear |
| Amber N Edinoff, Hamza Mohammad-Amin, Amira S Odish. Silent Neuroleptic Malignant Syndrome: A Case Report of Atypical Antipsychotic Induced Elevation of Creatinine Kinase and Altered Mental Status. Health psychology research. vol 10. issue 3. 2022-08-24. PMID:35999974. |
34-year-old african american male with a diagnosis of schizophrenia was placed on aripiprazole and risperidone for psychosis and mood stabilization. |
2022-08-24 |
2023-08-14 |
Not clear |
| Liang Fang, Ying Xu, Xuefei Tong, Xue Wu, Xiaomeng Zho. Efficacy of Risperidone Orally Disintegrating Tablets Combined with Oxazepam in the Treatment of Schizophrenia. Evidence-based complementary and alternative medicine : eCAM. vol 2022. 2022-08-22. PMID:35990853. |
efficacy of risperidone orally disintegrating tablets combined with oxazepam in the treatment of schizophrenia. |
2022-08-22 |
2023-08-14 |
Not clear |